Background: Stereotactic brain biopsy (SBB) is a technique that allows for definitive
noted in 56/69 biopsy samples. Smaller tumors and fewer SBB specimens obtained were significantly associated with diagnostic discordance.
Conclusions and Clinical Importance:
The DA of SBB readily allows for the diagnosis of common brain tumors in dogs. Although glioma grade discordance was frequent, diagnoses obtained from SBB are sufficient to currently inform therapeutic decisions.
Multiple SBB specimens should be collected to maximize DA. intra-axial brain lesions on MRI, as many as 47% of cerebrovascular accidents were misdiagnosed as gliomas, and up to 12% of gliomas were misclassified as strokes. 2 Given the current limitations of diagnostic imaging, acquisition of representative samples of brain tissue that allow a neuropathologist to provide a definitive diagnosis remains integral to informing best clinical practices regarding the selection of treatment for patients with brain disease. To meet this diagnostic need, minimally invasive stereotactic methods were introduced into neurosurgical practice in human medicine over a century ago and have evolved continuously since that time. To date, stereotactic brain biopsy (SBB) remains 1 of the most commonly performed stereotactic procedures. 3, 4 Diagnoses sufficient to guide therapeutic decision making are obtained in 95% of humans in which SBB is performed, with a low risk of associated adverse events. 4 Few reports describe the clinical utility of SBB procedures performed in dogs with intracranial diseases. 5, 6 Specific measures of the diagnostic utility of histopathological samples obtained using biopsy techniques include diagnostic yield (DY), which is the proportion of biopsy specimens producing a specific pathological diagnosis. The DY is calculated by dividing the number of biopsy specimens producing a specific pathological diagnosis by the total number of biopsies performed.
In dogs with intracranial lesions, the DY of SBB has been reported to be 95%. 5 Our objectives were to determine if the neuropathologic diagnosis obtained by SBB, using tumor type and grade as diagnostic endpoints,
was an accurate representation of the entire lesion when compared to reference standard SR or necropsy specimens, and to identify any risk factors associated with diagnostic discordance. We hypothesized that the DA of SBB would be lower in dogs with gliomas than in those with meningiomas, and that DA would be positively correlated with the number of SBB specimens obtained in each patient.
| MATERIALS AND METHODS

| Study design
Retrospective observational study.
| Dog and tumor characteristics
The tumor were generated for individual contiguous T2W MRI slices, and volumes were calculated using ROI volume software. 5 All dogs in the study underwent SBB to further evaluate newly MRI-diagnosed brain mass lesions associated with clinical signs of intracranial disease.
A single clinician performed all SBB procedures in anesthetized dogs using a previously described frame-based technique. 5 Two different headframe systems were used for SBB, and all dogs in the study had SBB performed with computed tomographic (CT) guidance ( Figure 1 ). 5 In an attempt to decrease the risk of obtaining a nondiagnostic biopsy specimen, the neurosurgeon performing SBB intentionally avoided sampling necrotic or hemorrhagic areas. For intra-axial lesions with heterogeneous or ring-like patterns of contrast enhancement, biopsy specimens were obtained that included enhancing regions in an attempt to avoid sampling necrotic tumor areas (Figure 1 ). 5 Hemorrhagic foci were defined by hypointensity on T2* gradient echo sequences, or hyperattenuating regions on intraoperative pre-contrast computed tomography scans ( Figure 1 ). criteria. 8 Two pathologists later were tasked with reclassifying glial tumors after the recent release of the revised classification criteria for dogs, in which gliomas are graded in a binary fashion (high-versus low-grade). 9 During the review process, pathologists were asked to provide specific reasons for any samples that were determined to be nondiagnostic, and any comments regarding the samples that influenced their diagnostic conclusions. At least 6 weeks lapsed between a pathologist's review of each of the slide sets. In the event of diagnostic discordance between the 2 examining pathologists, the histopathologic diagnosis coded in the original pathology report for the specimen in question was used to arrive at a majority opinion. 3 | RESULTS
| Neuropathological review and tumor classification
| Dog and tumor characteristics
Thirty-one dogs were included in the study. The median age at diagno- Table 1 ).
| Neuropathological results and diagnostic agreement
Reference standard (SR, n = 14 or NE, n = 17) WHO neuropathological diagnoses included 10 astrocytomas (n = 1, Grade II; n = 1, Grade III;
and n = 8, Grade IV), 13 oligodendrogliomas (n = 4, Grade II and n = 9, The median number of SBB obtained was 2 (range, 1-4), and was not different between meningiomas and gliomas (P = .26; grade concordance using the revised canine glioma classification was were factors that were significantly associated with tumor grade discordance using the WHO system (Table 2 ).
| DISCUSSION
In our study, the DY of SBB was 94% and overall DA was 81%. These findings are similar to those of previously published studies of dogs and humans undergoing frame-based SBB, which report DY for neoplastic lesions ranging from 89 to 99% and DA of 63%-90%. 5, 6, [10] [11] [12] [13] [14] [15] [16] In both human and veterinary medicine, improvements in the DY and DA of brain biopsy have evolved in parallel with clinician experience, as well as with diagnostic imaging and surgical technologies. 5, 6, [10] [11] [12] [13] [14] [15] [16] To date, only 2 studies have reported the DA of needle biopsy in dogs with naturally occurring brain tumors. 6, 16 One investigation using a free-hand biopsy technique resulted in a DA of 13%, with diagnostic tumor type agreement noted between biopsy and necropsy in 1/8 cases. 16 Another study using a SBB procedure reported a DA of 91% (20/22 cases) in dogs with brain tumors. 6 Neither of these previous studies in dogs included analyses of tumor grade as a component of diagnostic concordance. Here, we report an accuracy of 97% (30/31 cases) for determination of tumor type. The excellent agreement between SBB and the reference standard tumor type diagnoses in this, and other studies, provides additional evidence that SBB is a sufficiently accurate technique to provide definitive histologic diagnoses of brain tumors and subsequently guide patient care. 6 Because meningiomas and gliomas account for 75%-90% of all primary brain tumors in dogs, the cohort of dogs reported here is an appropriate representation of potential candidates for SBB encountered in clinical practice. 6, 17 Diagnostic agreement for tumor type and grade was perfect for all meningiomas in our study, but no attempt was made to examine concordance with respect to meningioma histologic subtypes. As hypothesized, the DA of gliomas was lower than that of meningiomas. This finding is not unexpected given that meningiomas were significantly larger than gliomas, and more biopsy trajectories were used in meningioma cases. Although the number of biopsy specimens obtained was not statistically different between meningiomas and gliomas, usage of a higher number of biopsy trajectories may improve diagnostic agreement by providing a superior topographic representation of tumor histology.
All of the diagnostic discordance observed in our study occurred during evaluation of glial tumors, and the majority of disagreements were attributable to tumor grading. were noted using the WHO grading system. Pathologists in our study commented that the absence of the hallmark morphologic feature of necrosis in SBB specimens often precluded assignment of a Grade IV astrocytoma or Grade III oligodendroglioma (high-grade glioma) diagnosis. 9 This may represent a form of sampling bias, because the neurosurgeon performing SBB intentionally avoided necrotic tumor regions, given that obtaining biopsy specimens from necrotic areas accounts for a substantial proportion of nondiagnostic samples in studies of SBB in dogs and humans. 5, 11, 13, 15 Phenotypic heterogeneity within gliomas is well recognized to present diagnostic challenges to neuropathologists in human and veterinary medicine, especially when considering the sample size limitations inherent to SBB. 9, 15 Our findings further support usage of the revised canine glioma system to streamline and standardize glioma diagnosis in dogs.
Factors that were identified to significantly influence glioma grade discordance in our study were lesion volume, number of biopsies and humans has been reported previously as moderate. 5, 9, 18 Incorporation of joint training and multiple specimen review sessions for pathologists has been shown to improve DA and should be considered in future studies. 19 All of the dogs in our study received interventions including stereotactic radiotherapeutic, molecularly targeted biological, and other ablative therapies between the time SBB and reference standard tissue samples were collected. [20] [21] [22] Tumor phenotypes may change over time as a result of natural tumor progression or as a result of treatments administered. 11, 13, 15, 21 Although time elapsed between SBB and the reference standard was not shown to significantly influence diagnostic concordance in our study, the median time elapsed between SBB and reference standard diagnosis in cases with glioma grade discordance (126 days) was nearly twice as long as in cases demonstrating agreement (68 days). In addition, the only disagreement in tumor type diagnosis observed in our study also had the longest delay (372 days) between SBB and necropsy.
| CONCLUSIONS
The The sponsor had no role in the design, preparation, or writing of the manuscript, or in the decision to submit the article for publication.
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
The study was conducted in accordance with the guidelines of the Virginia Tech Institutional Animal Care and Use Committee (protocols 17-011, 17-203, 16-017, 15-221, 14-235, 12-014, and 08-218).
HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.
ORCID
John H. Rossmeisl https://orcid.org/0000-0003-1655-7076
